Organon & Co. (OGN)
NYSE: OGN · Real-Time Price · USD
6.19
-0.08 (-1.28%)
Mar 20, 2026, 12:43 PM EDT - Market open
Organon & Co. Employees
Organon & Co. had 10,000 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
10,000
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$621,600
Profits / Employee
$18,700
Market Cap
1.61B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 10,000 | 0 | - |
| Dec 31, 2024 | 10,000 | 0 | - |
| Dec 31, 2023 | 10,000 | 0 | - |
| Dec 31, 2022 | 10,000 | 700 | 7.53% |
| Dec 31, 2021 | 9,300 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pfizer | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| GSK plc | 66,841 |
| Bristol-Myers Squibb Company | 32,500 |
| Grifols | 23,737 |
| Biogen | 7,500 |
| Amarin Corporation | 80 |
OGN News
- 17 days ago - KDventures announces that Organon has discontinued the development of the previous portfolio company Forendos' drug candidate for PCOS - GlobeNewsWire
- 21 days ago - New Analysis of Organon's VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis - Business Wire
- 25 days ago - Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals' Hormone-Free Intrauterine Device - Business Wire
- 26 days ago - Organon: Revenue Decline, Margin Pressure, And Strategic Uncertainty - Seeking Alpha
- 5 weeks ago - Organon Q4 Earnings Review: Poor Results Trigger Predictable Sell-Off - Seeking Alpha
- 5 weeks ago - Organon & Co. (OGN) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025 - Business Wire
- 7 weeks ago - Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026 - Business Wire